Skip to main content Accessibility help
×
Home

High acetylsalicylic acid dosing in infants after modified Blalock–Taussig shunt

  • Arun Saini (a1) (a2), Ashwini D. Joshi (a3), Krista M. Cowan (a3), Connor Wayne Gatewood (a3), Susheel T. K. Kumar (a4), Jerry Allen (a4), Samir H. Shah (a1), Simonne S. Nouer (a5), Tamekia Jones (a5) (a6), Christopher J. Knott-Craig (a4) and Umar S. Boston (a4)...

Abstract

Objective

Shunt-related adverse events are frequent in infants after modified Blalock–Taussig despite use of acetylsalicylic acid prophylaxis. A higher incidence of acetylsalicylic acid-resistance and sub-therapeutic acetylsalicylic acid levels has been reported in infants. We evaluated whether using high-dose acetylsalicylic acid can decrease shunt-related adverse events in infants after modified Blalock–Taussig.

Methods

In this single-centre retrospective cohort study, we included infants ⩽1-year-old who underwent modified Blalock–Taussig placement and received acetylsalicylic acid in the ICU. We defined acetylsalicylic acid treatment groups as standard dose (⩽7 mg/kg/day) and high dose (⩾8 mg/kg/day) based on the initiating dose.

Results

There were 34 infants in each group. Both groups were similar in age, gender, cardiac defect type, ICU length of stay, and time interval to second stage or definitive repair. Shunt interventions (18 versus 32%, p=0.16), shunt thrombosis (14 versus 17%, p=0.74), and mortality (9 versus 12%, p=0.65) were not significantly different between groups. On multiple logistic regression analysis, single-ventricle morphology (odds ratio 5.2, 95% confidence interval of 1.2–23, p=0.03) and post-operative red blood cells transfusion ⩾24 hours [odds ratio 15, confidence interval of (3–71), p<0.01] were associated with shunt-related adverse events. High-dose acetylsalicylic acid treatment [odds ratio 2.6, confidence interval of (0.7–10), p=0.16] was not associated with decrease in these events.

Conclusions

High-dose acetylsalicylic acid may not be sufficient in reducing shunt-related adverse events in infants after modified Blalock–Taussig. Post-operative red blood cells transfusion may be a modifiable risk factor for these events. A randomised trial is needed to determine appropriate acetylsalicylic acid dosing in infants with modified Blalock–Taussig.

Copyright

Corresponding author

Author for correspondence: A. Saini, Division of Pediatric Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine, 6651 Main street, MC E1420, Houston, TX, 77030, USA. Tel: +1 8238259478; Fax: +1 8328255929; E-mail: asaini@bcm.edu

Footnotes

Hide All

Cite this article: Saini A, Joshi AD, Cowan KM, Wayne Gatewood C, Kumar STK, Allen J, Shah SH, Nouer SS, Jones T, Knott-Craig CJ, Boston US. (2019) High acetylsalicylic acid dosing in infants after modified Blalock–Taussig shunt. Cardiology in the Young29: 389–397. doi: 10.1017/S1047951118002536

Footnotes

References

Hide All
1. Ahmad, U, Fatimi, SH, Naqvi, I, et al. Modified Blalock–Taussig shunt: immediate and short-term follow-up results in neonates. Heart Lung Circ 2008; 17: 5458.
2. Guzzetta, NA, Foster, GS, Mruthinti, N, Kilgore, PD, Miller, BE, Kanter, KR. In-hospital shunt occlusion in infants undergoing a modified Blalock–Taussig shunt. Ann Thorac Surg 2013; 96: 176182.
3. Gedicke, M, Morgan, G, Parry, A, Martin, R, Tulloh, R. Risk factors for acute shunt blockage in children after modified Blalock–Taussig shunt operations. Heart Vessels 2010; 25: 405409.
4. Celestin, C, Guillot, M, Ross-Ascuitto, N, Ascuitto, R. Computational fluid dynamics characterization of blood flow in central aorta to pulmonary artery connections: importance of shunt angulation as a determinant of shear stress-induced thrombosis. Pediatr Cardiol. 2015; 36: 600615.
5. Adipurnama, I, Yang, MC, Ciach, T, Butruk-Raszeja, B. Surface modification and endothelialization of polyurethane for vascular tissue engineering applications: a review. Biomater Sci 2016; 5: 2237.
6. Toulon, P, Berruyer, M, Brionne-Francois, M, et al. Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. Thromb Haemost 2016; 116: 916.
7. Del Vecchio, A, Motta, M, Romagnoli, C. Neonatal platelet function. Clin Perinatol 2015; 42: 625638.
8. Mir, A, Frank, S, Journeycake, J, et al. Aspirin resistance in single-ventricle physiology: aspirin prophylaxis is not adequate to inhibit platelets in the immediate postoperative period. Ann Thorac Surg 2015; 99: 21582164.
9. Agarwal, A, Firdouse, M, Brar, N, et al. Incidence and management of thrombotic and thromboembolic complications following the Norwood procedure: a systematic review. Clin Appl Thromb/Hemost: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2017; 23: 911921.
10. Li, JS, Yow, E, Berezny, KY, et al. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference? Circulation 2007; 116: 293297.
11. Emani, S, Trainor, B, Zurakowski, D, et al. Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery. J Thorac Cardiovasc Surg 2014; 148: 810814; discussion 4-6.
12. Heistein, LC, Scott, WA, Zellers, TM, et al. Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. Pediatr Cardiol 2008; 29: 285291.
13. Truong, DT, Johnson, JT, Bailly, DK, et al. Platelet inhibition in shunted infants on aspirin at short and midterm follow-up. Pediatr Cardiol 2017; 38: 401409.
14. Lev, EI, Solodky, A, Harel, N, et al. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol 2010; 55: 114121.
15. Gurbel, PA, Bliden, KP, DiChiara, J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 31563164.
16. Monagle, P, Chan, AKC, Goldenberg, NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): e737Se801S.
17. Cholette, JM, Rubenstein, JS, Alfieris, GM, et al. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. Ann Thorac Surg 2007; 84: 13201325.
18. Fenton, KN, Siewers, RD, Rebovich, B, Pigula, FA. Interim mortality in infants with systemic-to-pulmonary artery shunts. Ann Thorac Surg 2003; 76: 152156; discussion 6-7.
19. Rajasekhar, D, Kestin, AS, Bednarek, FJ, Ellis, PA, Barnard, MR, Michelson, AD. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost 1994; 72: 957963.
20. Straub, A, Smolich, J, d’Udekem, Y, Brizard, C, Peter, K, Horton, S. Activation of platelets in young infants during cardiopulmonary bypass. Thromb Haemost 2010; 103: 466469.
21. Manlhiot, C, Brandao, LR, Kwok, J, et al. Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation. J Pediatr 2012; 161: 513519 e3.
22. Todd Tzanetos, DR, Yu, C, Hernanz-Schulman, M, Barr, FE, Brown, NJ. Prospective study of the incidence and predictors of thrombus in children undergoing palliative surgery for single ventricle physiology. Intensive Care Med 2012; 38: 105112.
23. Redford, DT, Paidy, SR, Steinbrenner, EB, Nielsen, VG. Effects of profound hypoxemia on coagulation & fibrinolysis in normal individuals. Blood Coagul Fibrinolysis: An International Journal in Haemostasis and Thrombosis 2016; 27: 228231.
24. Mace, S, Borkat, G, Liebman, J. Hepatic dysfunction and cardiovascular abnormalities. Occurrence in infants, children, and young adults. Am J Dis Child 1985; 139: 6065.
25. Haga, P, Cotes, PM, Till, JA, Minty, BD, Shinebourne, EA. Serum immunoreactive erythropoietin in children with cyanotic and acyanotic congenital heart disease. Blood. 1987; 70: 822826.
26. Cholette, JM, Swartz, MF, Rubenstein, J, et al. Outcomes using a conservative versus liberal red blood cell transfusion strategy in infants requiring cardiac operation. Ann Thorac Surg 2017; 103: 206214.
27. Garcia-Roa, M, Del Carmen Vicente-Ayuso, M, Bobes, AM, et al. Red blood cell storage time and transfusion: current practice, concerns and future perspectives. Blood Transfus. 2017; 15: 222231.
28. Anderson, BR, Blancha, VL, Duchon, JM, et al. The effects of postoperative hematocrit on shunt occlusion for neonates undergoing single ventricle palliation. J Thorac Cardiovasc Surg 2017; 153: 947955.
29. Sahoo, TK, Chauhan, S, Sahu, M, Bisoi, A, Kiran, U. Effects of hemodilution on outcome after modified Blalock-Taussig shunt operation in children with cyanotic congenital heart disease. J Cardiothorac Vasc Anesth 2007; 21: 179183.
30. Manlhiot, C, McCrindle, BW, Menjak, IB, et al. Longer blood storage is associated with suboptimal outcomes in high-risk pediatric cardiac surgery. Ann Thorac Surg 2012; 93: 15631569.
31. Howard-Quijano, K, Schwarzenberger, JC, Scovotti, JC, et al. Increased red blood cell transfusions are associated with worsening outcomes in pediatric heart transplant patients. Anesth Analg 2013; 116: 12951308.
32. Dasgupta, R, Parsons, A, McClelland, S, et al. Association of haematocrit and red blood cell transfusion with outcomes in infants with shunt-dependent pulmonary blood flow and univentricular physiology. Blood Transfus 2015; 13: 417422.

Keywords

Related content

Powered by UNSILO
Type Description Title
WORD
Supplementary materials

Saini et al. supplementary material
Saini et al. supplementary material 1

 Word (85 KB)
85 KB

High acetylsalicylic acid dosing in infants after modified Blalock–Taussig shunt

  • Arun Saini (a1) (a2), Ashwini D. Joshi (a3), Krista M. Cowan (a3), Connor Wayne Gatewood (a3), Susheel T. K. Kumar (a4), Jerry Allen (a4), Samir H. Shah (a1), Simonne S. Nouer (a5), Tamekia Jones (a5) (a6), Christopher J. Knott-Craig (a4) and Umar S. Boston (a4)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.